143 related articles for article (PubMed ID: 2515811)
21. Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients.
Franssen AM; Rolland R; Chadha DR; Willemsen WN; Vemer HM
Eur J Obstet Gynecol Reprod Biol; 1986 Dec; 23(5-6):379-86. PubMed ID: 3100357
[TBL] [Abstract][Full Text] [Related]
22. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
[TBL] [Abstract][Full Text] [Related]
23. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
Raitz von Frentz M; Schweppe KW
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
25. Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience).
Cirkel U; Schweppe KW; Ochs H; Schneider HP
Prog Clin Biol Res; 1986; 225():189-99. PubMed ID: 3097665
[No Abstract] [Full Text] [Related]
26. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
Baumann R; Kuhl H; Taubert HD; Sandow J
Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of gonadotropin-releasing hormone agonist (buserelin) in the treatment of endometriosis.
Rönnberg L; Koskimies A; Laatikainen T; Ranta T; Saastamoinen J
Acta Obstet Gynecol Scand; 1989; 68(1):49-53. PubMed ID: 2508418
[TBL] [Abstract][Full Text] [Related]
28. [Hormonal changes in buserelin therapy].
Fuchs U; Zwirner M
Zentralbl Gynakol; 1989; 111(18):1236-40. PubMed ID: 2511705
[TBL] [Abstract][Full Text] [Related]
29. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
[TBL] [Abstract][Full Text] [Related]
30. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
[TBL] [Abstract][Full Text] [Related]
31. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
Brogden RN; Buckley MM; Ward A
Drugs; 1990 Mar; 39(3):399-437. PubMed ID: 2109679
[TBL] [Abstract][Full Text] [Related]
32. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
33. Gonadotrophin releasing hormone agonist (buserelin) in the treatment of endometriosis: changes in the extent of the disease and in CA 125 serum levels after 6-month therapy.
Marana R; Muzii L; Muscatello P; Lanzone A; Caruso A; Dell'Acqua S; Mancuso S
Br J Obstet Gynaecol; 1990 Nov; 97(11):1016-9. PubMed ID: 2147564
[TBL] [Abstract][Full Text] [Related]
34. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
[No Abstract] [Full Text] [Related]
35. Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women.
Lemay A; Faure N; Labrie F
Fertil Steril; 1982 Feb; 37(2):193-200. PubMed ID: 6800846
[TBL] [Abstract][Full Text] [Related]
36. [Metabolic effects and general side effects in the treatment of endometriosis with an LHRH agonist].
Cirkel U; Schweppe KW; Ochs H; Schneider HP
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):154-7. PubMed ID: 3108065
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
39. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.
Lemay A
Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859
[No Abstract] [Full Text] [Related]
40. Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase.
Lemay A; Sandow J; Bureau M; Maheux R; Fontaine JY; Mérat P
Fertil Steril; 1988 Mar; 49(3):410-7. PubMed ID: 3125068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
